Jeil Pharm (002620) - Net Assets

Latest as of March 2026: ₩475.12 Billion KRW ≈ $321.98 Million USD

Based on the latest financial reports, Jeil Pharm (002620) has net assets worth ₩475.12 Billion KRW (≈ $321.98 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩878.26 Billion ≈ $595.18 Million USD) and total liabilities (₩403.14 Billion ≈ $273.20 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002620 tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩475.12 Billion
% of Total Assets	54.1%
Annual Growth Rate	5.18%
5-Year Change	-6.24%
10-Year Change	86.1%
Growth Volatility	70.03

Jeil Pharm - Net Assets Trend (2011–2025)

This chart illustrates how Jeil Pharm's net assets have evolved over time, based on quarterly financial data. See 002620 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Jeil Pharm (2011–2025)

The table below shows the annual net assets of Jeil Pharm from 2011 to 2025. For live valuation and market cap data, see 002620 market cap overview.

Year	Net Assets	Change
2025-12-31	₩469.12 Billion ≈ $317.91 Million	+7.25%
2024-12-31	₩437.40 Billion ≈ $296.42 Million	+8.75%
2023-12-31	₩402.19 Billion ≈ $272.56 Million	-4.19%
2022-12-31	₩419.79 Billion ≈ $284.49 Million	-16.09%
2021-12-31	₩500.31 Billion ≈ $339.06 Million	+0.21%
2020-12-31	₩499.28 Billion ≈ $338.36 Million	+3.36%
2019-12-31	₩483.04 Billion ≈ $327.35 Million	-18.07%
2018-12-31	₩589.58 Billion ≈ $399.55 Million	+245.92%
2017-12-31	₩170.44 Billion ≈ $115.50 Million	-32.39%
2016-12-31	₩252.08 Billion ≈ $170.83 Million	+4.43%
2015-12-31	₩241.39 Billion ≈ $163.59 Million	-0.01%
2012-12-31	₩241.41 Billion ≈ $163.60 Million	+4.33%
2011-12-31	₩231.40 Billion ≈ $156.81 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jeil Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 81.3% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	₩38.27 Billion	12.01%
Other Components	₩280.47 Billion	87.99%
Total Equity	₩318.74 Billion	100.00%

Jeil Pharm Competitors by Market Cap

The table below lists competitors of Jeil Pharm ranked by their market capitalization.

Company	Market Cap
Medipower -M TA:MDPR	$77.51 Million
Taiwan Alpha Electronic Co Ltd TWO:6204	$77.51 Million
Freightos Limited Ordinary shares NASDAQ:CRGO	$77.53 Million
Petrolimex Insurance Corp VN:PGI	$77.53 Million
Delfingen PA:ALDEL	$77.48 Million
Credit Clear Ltd AU:CCR	$77.47 Million
Tradetool Auto Co Ltd TWO:3685	$77.47 Million
GO Element Co. Ltd. KQ:311320	$77.45 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jeil Pharm's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 306,949,796,440 to 318,740,640,250, a change of 11,790,843,810 (3.8%).
Net income of 14,635,277,020 contributed positively to equity growth.
Dividend payments of 183,173,820 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	₩14.64 Billion	+4.59%
Dividends Paid	₩183.17 Million	-0.06%
Other Changes	₩-2.66 Billion	-0.83%
Total Change	₩-	3.84%

Book Value vs Market Value Analysis

This analysis compares Jeil Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.36x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.17x to 0.36x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	₩44781.97	₩7450.00	x
2018-12-31	₩31941.23	₩7450.00	x
2019-12-31	₩25632.11	₩7450.00	x
2020-12-31	₩26542.15	₩7450.00	x
2021-12-31	₩26820.87	₩7450.00	x
2022-12-31	₩22002.60	₩7450.00	x
2023-12-31	₩20810.28	₩7450.00	x
2024-12-31	₩19995.26	₩7450.00	x
2025-12-31	₩20763.34	₩7450.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jeil Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 4.59%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 2.23%
• Asset Turnover: 0.75x
• Equity Multiplier: 2.75x
Recent ROE (4.59%) is below the historical average (21.22%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2011	11.67%	5.84%	1.20x	1.66x	₩3.88 Billion
2012	4.63%	2.62%	1.09x	1.62x	₩-12.97 Billion
2015	4.04%	1.64%	1.34x	1.84x	₩-14.38 Billion
2016	3.17%	1.28%	1.25x	1.98x	₩-17.00 Billion
2017	311.16%	1167.44%	0.22x	1.19x	₩502.14 Billion
2018	1.44%	4.95%	0.16x	1.88x	₩-41.96 Billion
2019	-23.04%	-12.50%	0.86x	2.15x	₩-130.01 Billion
2020	2.81%	1.50%	0.86x	2.18x	₩-29.31 Billion
2021	-0.85%	-0.46%	0.85x	2.17x	₩-44.66 Billion
2022	-22.07%	-9.40%	0.92x	2.56x	₩-108.33 Billion
2023	-5.09%	-2.02%	0.91x	2.75x	₩-48.20 Billion
2024	-16.67%	-6.56%	0.88x	2.90x	₩-81.85 Billion
2025	4.59%	2.23%	0.75x	2.75x	₩-17.24 Billion

Industry Comparison

This section compares Jeil Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $447,413,293,348
Average return on equity (ROE) among peers: 3.37%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jeil Pharm (002620)	₩475.12 Billion	11.67%	0.85x	$77.50 Million
Dongwha Pharm.Co.Ltd (000020)	$297.40 Billion	3.39%	0.25x	$100.12 Million
Yuhan Corp. (000100)	$592.86 Billion	10.31%	0.52x	$3.95 Billion
Yuhan Corp Preferred (000105)	$2.15 Trillion	3.29%	0.37x	$52.37 Million
Yuyu Pharma (000220)	$90.54 Billion	5.22%	0.52x	$44.69 Million
Yuyu Pharma Inc (000225)	$71.49 Billion	-10.45%	0.42x	$15.29 Million
Yuyu Pharma Inc (000227)	$117.04 Billion	1.10%	0.32x	$42.41 Million
Ildong Holdings Co Ltd (000230)	$310.17 Billion	8.80%	0.65x	$56.70 Million
Samil Pharm (000520)	$62.87 Billion	0.00%	0.77x	$102.87 Million
Donga Socio Holdings (000640)	$580.35 Billion	10.90%	0.82x	$366.94 Million
Jw Pharmac (001060)	$200.74 Billion	1.12%	1.94x	$426.35 Million

About Jeil Pharm

KO:002620 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$77.50 Million

₩114.37 Billion KRW

Market Cap Rank

#20299 Global

#1096 in Korea

Share Price

₩7450.00

Change (1 day)

+2.90%

52-Week Range

₩6990.00 - ₩9280.00

All Time High

₩92178.44